Information Provided By: 
Fly News Breaks for July 5, 2016
ALKS
Jul 5, 2016 | 07:02 EDT
Citi analyst Liav Abraham raised her price target for Alkermes to $44 citing pipeline updates and updated thoughts on Vivitrol and Aristada. The analyst keeps a Neutral rating on the shares, however, saying her expectations for positive FORWARD-5 headline data in Q4 remain low. Abraham highlights the "the continued positive trajectory" in Vivitrol scrip trends. She expects this trend to continue as anti-opioid treatment funding increases.
News For ALKS From the Last 2 Days
